Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could starting dialysis sooner save more hearts?

NCT ID NCT07756801

Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial asks whether starting dialysis early—within 6 hours—in patients with cardiogenic shock and fluid overload can reduce deaths in the hospital compared to waiting until it's clearly needed. It enrolls adults in intensive care with severe heart pump failure and signs of excess fluid. The study compares immediate dialysis to the current standard of care, tracking survival, need for additional heart support, and recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Immediate renal replacement therapy (dialysis) started within 6 hours of randomization
What this could lead to
If early dialysis proves better, it could establish a new standard of care that lowers death rates in critically ill patients with cardiogenic shock and fluid overload.
What could go wrong
The trial is still testing this approach, and early dialysis carries risks like infection, blood pressure drops, and complications from the procedure. It may not improve outcomes and could add unnecessary treatment burden.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 456 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adult patients \>/= 18 years of age admitted to an intensive care unit * Diagnosed clinically with Society for Cardiovascular Angiography and Interventions (SCAI) Class C or D cardiogenic shock * Clinical or hemodynamic evidence of volume overload Exclusion Criteria: * Patients whose care plan, as determined by the treating clinical team, will not include renal replacement therapy * Decision has already been made by the treating clinical team to initiate renal replacement therapy * Hyperkalemia with serum potassium \>/= 6mmol/L at the time of screening * Severe metabolic acidosis with serum bicarbonate \</= 12 mmol/L at the time of screening * Severe azotemia with serum urea \>/= 40 mmol/L at the time of screening * Acute intoxication necessitating use of renal replacement therapy * Recent renal replacement therapy (within 30 days) * Known end-stage renal disease (defined as an estimated glomerular filtration rate \<15 ml/min/1.73m2 * presentation with out-of-hospital cardiac arrest

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiogenic shock Edema Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock Hypervolemia Renal replacement therapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.